Sesen Bio Competitors

Sesen Bio (NASDAQ:SESN) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and FibroGen, as provided by MarketBeat.com.

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. FibroGen has a consensus price target of $45.8333, suggesting a potential upside of 146.81%. Given Sesen Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than FibroGen.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 75.1% of FibroGen shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Comparatively, 3.4% of FibroGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and FibroGen's revenue, earnings per share (EPS) and valuation.

FibroGen has higher revenue and earnings than Sesen Bio. FibroGen is trading at a lower price-to-earnings ratio than Sesen Bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sesen Bio has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.

Profitability

This table compares Sesen Bio and FibroGen's net margins, return on equity and return on assets.

Summary

Sesen Bio beats FibroGen on 7 of the 12 factors compared between the two stocks.

Sesen Bio (NASDAQ:SESN) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and Cassava Sciences, as provided by MarketBeat.com.

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Cassava Sciences has a consensus price target of $35.3333, suggesting a potential downside of 15.00%. Given Sesen Bio's higher possible upside, research analysts plainly believe Sesen Bio is more favorable than Cassava Sciences.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Comparatively, 13.7% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and Cassava Sciences' revenue, earnings per share (EPS) and valuation.

Cassava Sciences is trading at a lower price-to-earnings ratio than Sesen Bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sesen Bio has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares Sesen Bio and Cassava Sciences' net margins, return on equity and return on assets.

Summary

Cassava Sciences beats Sesen Bio on 6 of the 10 factors compared between the two stocks.

Sesen Bio (NASDAQ:SESN) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and ADC Therapeutics, as provided by MarketBeat.com.

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. ADC Therapeutics has a consensus price target of $47.50, suggesting a potential upside of 98.00%. Given Sesen Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than ADC Therapeutics.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and ADC Therapeutics' revenue, earnings per share (EPS) and valuation.

Sesen Bio has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Sesen Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sesen Bio and ADC Therapeutics' net margins, return on equity and return on assets.

Summary

Sesen Bio beats ADC Therapeutics on 6 of the 10 factors compared between the two stocks.

Sesen Bio (NASDAQ:SESN) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and Myovant Sciences, as provided by MarketBeat.com.

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Myovant Sciences has a consensus price target of $31.1667, suggesting a potential upside of 71.72%. Given Sesen Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than Myovant Sciences.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 33.8% of Myovant Sciences shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Comparatively, 3.9% of Myovant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and Myovant Sciences' revenue, earnings per share (EPS) and valuation.

Sesen Bio is trading at a lower price-to-earnings ratio than Myovant Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sesen Bio has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.99, indicating that its share price is 199% more volatile than the S&P 500.

Profitability

This table compares Sesen Bio and Myovant Sciences' net margins, return on equity and return on assets.

Summary

Sesen Bio beats Myovant Sciences on 6 of the 10 factors compared between the two stocks.

Sesen Bio (NASDAQ:SESN) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and Prelude Therapeutics, as provided by MarketBeat.com.

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Prelude Therapeutics has a consensus price target of $54.25, suggesting a potential upside of 53.86%. Given Sesen Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than Prelude Therapeutics.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 76.2% of Prelude Therapeutics shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and Prelude Therapeutics' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Sesen Bio and Prelude Therapeutics' net margins, return on equity and return on assets.

Summary

Sesen Bio beats Prelude Therapeutics on 4 of the 6 factors compared between the two stocks.

Sesen Bio (NASDAQ:SESN) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and Ironwood Pharmaceuticals, as provided by MarketBeat.com.

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Ironwood Pharmaceuticals has a consensus price target of $11.40, suggesting a potential upside of 11.87%. Given Sesen Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than Ironwood Pharmaceuticals.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and Ironwood Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Ironwood Pharmaceuticals has higher revenue and earnings than Sesen Bio. Sesen Bio is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sesen Bio has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares Sesen Bio and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Ironwood Pharmaceuticals beats Sesen Bio on 8 of the 13 factors compared between the two stocks.